IMCR:NASDAQImmunocore Holdings plc Analysis

Immunocore is trading just above its short‑term moving average while still lagging the longer‑term averages, suggesting a neutral price bias. The RSI sits in the mid‑range, the MACD shows a bearish divergence, and volume has been trending lower, all pointing to limited short‑term upside.
However, the company reported solid first‑quarter sales growth, a strong cash position relative to debt, and an expanding pipeline with multiple Phase 3 trials, which together underpin a substantial upside potential relative to its discounted cash‑flow estimate. The negative earnings multiples reflect the current loss profile rather than valuation deficiency, and the market appears to be pricing in a sizable discount.